BridgeBio Pharma to Present Long-Term Acoramidis Data at ACC Scientific Sessions

关键事实

1BridgeBio Pharma will present long-term efficacy and safety data for acoramidis from the ATTRibute-CM OLE trial.

2The data will be shared in a late-breaking oral presentation at the ACC Annual Scientific Sessions on March 28-30, 2026.

3The presentation focuses on Phase 3 open-label extension (OLE) results for patients with transthyretin amyloid cardiomyopathy (ATTR-CM).

BridgeBio Pharma has announced it will present long-term efficacy and safety data for its drug, acoramidis, at the upcoming American College of Cardiology (ACC) Annual Scientific Sessions. The data, derived from the Phase 3 ATTRibute-CM open-label extension (OLE) trial, will be featured in a late-breaking oral presentation. This presentation is scheduled to take place between March 28 and March 30, 2026, highlighting the drug's performance in treating transthyretin amyloid cardiomyopathy (ATTR-CM). Acoramidis remains a critical asset in BridgeBio's clinical pipeline, and these long-term results are essential for its market positioning. Industry experts view late-breaking presentations at major medical conferences as significant catalysts for biotechnology stocks. Positive outcomes could potentially enhance the drug's competitive profile against existing treatments for ATTR-CM.

免费注册以访问此内容

创建免费账户